A new era in therapeutic innovation is dawning, marked by the successful Phase IIa clinical trial results for Hybridopa, an…
Read More
As Cell Therapies Scale and CDMOs Cut Staff, Process Know-How Is Often Getting Lost in Tech Transfer
The biopharmaceutical industry is grappling with a critical challenge: the silent erosion of invaluable "tacit knowledge" during technology transfer processes.…
Read More
What if psilocybin works about as well for depression as an SSRI?
Emerging data from recent studies and meta-analyses suggest that the highly anticipated efficacy of classic psychedelics, particularly psilocybin, in treating…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The therapeutic landscape for glucagon-like peptide-1 (GLP-1) receptor agonists has undergone a monumental transformation, extending far beyond its initial applications…
Read More
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
In a significant advancement for precision oncology, ConcertAI, a leading AI and real-world data company focused on cancer care, has…
Read More
The Oral GLP-1 Revolution: Unpacking the Scientific and Clinical Impact of Small Molecules
The pharmaceutical landscape for metabolic disorders, particularly Type 2 Diabetes and obesity, is undergoing a profound transformation, heralded by the…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The U.S. pharmaceutical landscape, historically characterized by higher drug prices compared to other developed nations, is undergoing a significant transformation,…
Read More
Insuring the Trip: An Underwriter on What It Will Take for Approved Psilocybin to Become a Real Business
The landscape of mental health treatment is on the cusp of a profound transformation, with psilocybin, a compound once relegated…
Read More
PharmSci 360 2026 Heads to New Orleans This October
The American Association of Pharmaceutical Scientists (AAPS) is set to host its premier annual gathering, PharmSci 360, from October 25…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…
Read More
